What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations

Publikation

What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations

Wissenschaftlicher Artikel/Review - 01.10.2018

Yu Evan Y, Gillessen Sommer Silke, Mottet Nicolas

Zitation

Yu E, Gillessen Sommer S, Mottet N. What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations. Eur Urol Focus 2018

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Eur Urol Focus 2018

Veröffentlichungsdatum

01.10.2018

eISSN (Online)

2405-4569

Kurzbeschreibung/Zielsetzung

Clinical trial data forms the foundation of how we treat men with metastatic prostate cancer who are initiating therapy. However, clinical trial data does not answer everything; hence, good clinical practice, pragmatism, and occasionally extrapolation drives how we manage these patients. Fortunately, multiple international guideline committees meet regularly and offer clinical guidance. In this mini-review, we focus on the United States National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology (EAU) recommendations for the initial treatment of metastatic prostate cancer.